Literature DB >> 1928199

Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters.

D R Graham1, M M Keldermans, L W Klemm, N J Semenza, M L Shafer.   

Abstract

Rates of bacteremia among hospitalized patients with central venous catheters range up to 21%. Few data exist for home intravenous therapy (IVT). We studied 300 patients from two hospital-based home IVT services in 29 months. Diagnoses included 92 cases of osteomyelitis, 33 of pneumonia, 35 of malnutrition, 26 of chronic pain, and 114 of other diseases. Peripheral IVT was given to 97 patients. Mean age was 39.4 years (range, 0.3-98). Hickman, Infuse-A-Port, Broviac, Arrow triple lumen, Hohn, and peripherally inserted central catheters (PICC) were used for a mean of 44 days. Six bacteremias (one death) (2%, 4.6/10,000 catheter days), two subclavian thromboses, 13 catheter site infections, and one additional death occurred. PICC experience included 76 patients, mean age 46 years (range, 4-76), primarily with infections, chronic pain, or dehydration. Mean duration of therapy was 24 days (0-67) and was completed in 51 patients; others completed therapy with standard peripheral catheters a mean of 6 days later. Complications included 17 obstructions by clot, 11 cases of phlebitis, six catheter fractures, five punctures, two accidental removals, and one infiltration. Liquid silicone repaired holes; urokinase opened clots. Successful completion of therapy was more common in the second year, 88% versus 57%. Despite more complications, patients, home IVT nurses, and physicians preferred PICCs. We conclude that home IVT is safe via many means of access, with fewer infections than with hospital care. Such infections may be termed "nosohusial."

Entities:  

Mesh:

Year:  1991        PMID: 1928199     DOI: 10.1016/0002-9343(91)90351-w

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  A case of hypomagnesaemia due to malabsorption, unresponsive to oral administration of magnesium glycerophosphate, but responsive to oral magnesium oxide supplementation.

Authors:  J R Ross; P I Dargan; A L Jones; A Kostrzewski
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Hypomagnesaemia due to malabsorption is not always responsive to oral magnesium oxide supplementation alone.

Authors:  R P Arasaradnam; R P Bolton
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 3.  Intravenous long-lines in children with cystic fibrosis: a multidisciplinary approach.

Authors:  Mark A Turner; Veda Unsworth; Timothy J David
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 4.  Economics of home intravenous services.

Authors:  N D Thickson
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 5.  A practical guide to the diagnosis and management of bone and joint infections.

Authors:  J T Mader; D Mohan; J Calhoun
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 6.  Pediatric vascular access.

Authors:  James S Donaldson
Journal:  Pediatr Radiol       Date:  2006-03-15

7.  Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks?

Authors:  D N Williams
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

8.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

9.  Evaluation of different methods of securing intravenous catheters: measurement of forces during simulated accidental pullout.

Authors:  N Patel; C E Smith; A C Pinchak; D E Hancock
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

10.  Existing data sources for clinical epidemiology: The North Denmark Bacteremia Research Database.

Authors:  Henrik C Schønheyder; Mette Søgaard
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.